Research advances of monitoring and tracking chimeric antigen receptor T cell in vivo
-
Abstract: Chimeric antigen receptor T cells(CAR-T) therapy, in which T cells are genetically engineered to specifically recognize and kill targeted tumor cells, has been shown to be remarkably effective in the treatment of some refractory/recurrent leukemia and lymphoma. However, monitoring the migration and survival of CAR-T cells as well as quantifying their number and durability in vivo need further study, so that to determine their biodistribution of vital organs and tissues. A series of imaging techniques, enabling noninvasively continuous localization and dynamic tracking of cells infused in vivo, have provided us with ideas. This review summarizes several in vivo CAR-T cell trafficking techniques, which are expected to provide guidance for CAR-T therapy in clinical practice.
-
Key words:
- CAR-T cell /
- cell labeling /
- noninvasive tracking /
- dynamic monitoring
-
-
表 1 常见的报告基因及探针
报告基因 成像探针 显像模式 CAR-T靶点 验证模型 参考文献 HSV1-tk 18F-FHBG PET IL-13 zatakine 临床研究 [11-12] HSV1-sr39tk 18F-FHBG PET B7H3 小鼠骨肉瘤异种移植模型 [13] eDFHRhSSTR2 18F-TMP68Ga-DOTATOC PETPET GD2ICAM-1 小鼠骨肉瘤异种移植模型小鼠未分化甲状腺癌异种移植模型 [14][15] hPSMADAbR1 18F-DCFPyL86Y/177Lu-AABD PETPET/SPECT CD19CD19 小鼠急性淋巴细胞白血病异种移植模型小鼠急性淋巴细胞白血病皮下瘤异种移植模型 [16][17] hNIS 99mTcO4-18F-BF4-/99mTcO4- SPECTPET/SPECT PMSAPan-ErbB 小鼠前列腺癌异种移植模型小鼠乳腺癌异种移植模型 [18][19] 
下载: 导出CSV
表 2 常见的直接标记及显像探针
成像探针 标记方式 显像模式 CAR-T靶点 验证模型 参考文献 111In-羟喹啉 共孵育 SPECT HER2 临床研究 [27] 89Zr-DFO 共孵育 PET CD19 小鼠淋巴瘤异种移植模型 [28] 89Zr-羟喹啉 共孵育 PET IL-13Rα2和PSCA 小鼠胶质母细胞瘤和前列腺癌异种移植模型 [29] 89Zr-二氧化硅纳米标签 鱼精蛋白和肝素促入胞 PET/NIRF hCEA 小鼠腹腔卵巢癌异种移植模型 [30] 68Ga-羟喹啉 共孵育 PET CD19 小鼠伯基特淋巴瘤血液瘤模型及CD19(+)K562皮下瘤异种移植模型 [31] 64Cu-AuNPs 电穿孔 PET CD19 正常小鼠 [32] 89Zr-DFO-ICOS单抗 抗原-抗体结合 PET mCD19 鼠源性淋巴瘤模型 [33] PFC 共孵育 MRI EGFRvⅢ 小鼠胶质母细胞瘤异种移植模型 [34] TAT-PFC纳米乳剂 细胞穿膜肽引导入胞 MRI EGFRvⅢ 小鼠胶质母细胞瘤异种移植模型 [35] USPIO PLL中和作用促进内吞 MRI EGFRvⅢ 小鼠胶质母细胞瘤异种移植模型 [36]
下载: 导出CSV
-
[1] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells[J]. Nat Rev Cancer, 2021, 21(3): 145-161. doi: 10.1038/s41568-020-00323-z
[2] Fousek K, Watanabe J, Joseph SK, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression[J]. Leukemia, 2021, 35(1): 75-89. doi: 10.1038/s41375-020-0792-2
[3] Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management[J]. Blood Rev, 2019, 34: 45-55. doi: 10.1016/j.blre.2018.11.002
[4] Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies[J]. J Allergy Clin Immunol, 2020, 146(5): 940-948. doi: 10.1016/j.jaci.2020.07.025
[5] Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy[J]. J Hematol Oncol, 2016, 9(1): 70. doi: 10.1186/s13045-016-0299-5
[6] Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528. doi: 10.1016/S0140-6736(14)61403-3
[7] Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther, 2010, 18(4): 843-851. doi: 10.1038/mt.2010.24
[8] Hu Y, Huang J. The Chimeric Antigen Receptor Detection Toolkit[J]. Front Immunol, 2020, 11: 1770. doi: 10.3389/fimmu.2020.01770
[9] Liu Z, Li Z. Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes(CTLs)[J]. Theranostics, 2014, 4(10): 990-1001. doi: 10.7150/thno.9268
[10] Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods[J]. Nat Rev Clin Oncol, 2011, 8(11): 677-688. doi: 10.1038/nrclinonc.2011.141
[11] Yaghoubi SS, Jensen MC, Satyamurthy N, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma[J]. Nat Clin Pract Oncol, 2009, 6(1): 53-58. doi: 10.1038/ncponc1278
[12] Keu KV, Witney TH, Yaghoubi S, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma[J]. Sci Transl Med, 2017, 9(373): eaag2196. doi: 10.1126/scitranslmed.aag2196
[13] Murty S, Labanieh L, Murty T, et al. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors[J]. Cancer Res, 2020, 80(21): 4731-4740. doi: 10.1158/0008-5472.CAN-19-3579
[14] Sellmyer MA, Richman SA, Lohith K, et al. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene[J]. Mol Ther, 2020, 28(1): 42-51. doi: 10.1016/j.ymthe.2019.10.007
[15] Vedvyas Y, Shevlin E, Zaman M, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors[J]. JCI Insight, 2016, 1(19): e90064.
[16] Minn I, Huss DJ, Ahn HH, et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography[J]. Sci Adv, 2019, 5(7): eaaw5096. doi: 10.1126/sciadv.aaw5096
[17] Krebs S, Ahad A, Carter LM, et al. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes[J]. J Nucl Med, 2018, 59(12): 1894-1900. doi: 10.2967/jnumed.118.208041
[18] Emami-Shahri N, Foster J, Kashani R, et al. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells[J]. Nat Commun, 2018, 9(1): 1081. doi: 10.1038/s41467-018-03524-1
[19] Volpe A, Lang C, Lim L, et al. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models[J]. Mol Ther, 2020, 28(10): 2271-2285. doi: 10.1016/j.ymthe.2020.06.028
[20] Mccracken MN. Thymidine Kinase PET Reporter Gene Imaging of Cancer Cells In Vivo[J]. Methods Mol Biol, 2018, 1790: 137-151.
[21] Kurtz DM, Gambhir SS. Tracking cellular and immune therapies in cancer[J]. Adv Cancer Res, 2014, 124: 257-296.
[22] Black ME, Newcomb TG, Wilson HM, et al. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy[J]. Proc Natl Acad Sci U S A, 1996, 93(8): 3525-3529. doi: 10.1073/pnas.93.8.3525
[23] Mayer-Kuckuk P, Menon LG, Blasberg RG, et al. Role of reporter gene imaging in molecular and cellular biology[J]. Biol Chem, 2004, 385(5): 353-361.
[24] Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography[J]. Proc Natl Acad Sci U S A, 2000, 97(6): 2785-2790. doi: 10.1073/pnas.97.6.2785
[25] Eskandari S, Loo DD, Dai G, et al. Thyroid Na+/I-symporter. Mechanism, stoichiometry, and specificity[J]. J Biol Chem, 1997, 272(43): 27230-27238. doi: 10.1074/jbc.272.43.27230
[26] Bruno R, Giannasio P, Ronga G, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues[J]. J Endocrinol Invest, 2004, 27(11): 1010-1014. doi: 10.1007/BF03345302
[27] Stanton SE, Eary JF, Marzbani EA, et al. Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo[J]. J Immunother Cancer, 2016, 4: 27. doi: 10.1186/s40425-016-0131-3
[28] Lee SH, Soh H, Chung JH, et al. Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging[J]. PLoS One, 2020, 15(1): e0223814. doi: 10.1371/journal.pone.0223814
[29] Weist MR, Starr R, Aguilar B, et al. PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with(89) Zr-Oxine[J]. J Nucl Med, 2018, 59(10): 1531-1537. doi: 10.2967/jnumed.117.206714
[30] Harmsen S, Medine EI, Moroz M, et al. A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking[J]. Biomaterials, 2021, 269: 120630. doi: 10.1016/j.biomaterials.2020.120630
[31] Wang XY, Wang Y, Wu Q, et al. Feasibility study of(68) Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging[J]. Acta Pharmacol Sin, 2021, 42(5): 824-831. doi: 10.1038/s41401-020-00511-5
[32] Bhatnagar P, Li Z, Choi Y, et al. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64[J]. Integr Biol(Camb), 2013, 5(1): 231-238.
[33] Simonetta F, Alam IS, Lohmeyer JK, et al. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET[J]. Clin Cancer Res, 2021, 27(4): 1058-1068. doi: 10.1158/1078-0432.CCR-20-2770
[34] Chapelin F, Gao S, Okada H, et al. Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model[J]. Sci Rep, 2017, 7(1): 17748. doi: 10.1038/s41598-017-17669-4
[35] Hingorani DV, Chapelin F, Stares E, et al. Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection[J]. Magn Reson Med, 2020, 83(3): 974-987. doi: 10.1002/mrm.27988
[36] Xie T, Chen X, Fang J, et al. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging[J]. Cytotherapy, 2021, 23(3): 211-222. doi: 10.1016/j.jcyt.2020.10.006
[37] Marofi F, Abdul-Rasheed OF, Rahman HS, et al. CAR-NK cell in cancer immunotherapy; A promising frontier[J]. Cancer Sci, 2021, 112(9): 3427-3436. doi: 10.1111/cas.14993
[38] Manfredi F, Cianciotti BC, Potenza A, et al. TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals[J]. Front Immunol, 2020, 11: 1689. doi: 10.3389/fimmu.2020.01689
-